González Moreno, MaríaSaborido Alejandro, CristianTeira Serrano, David2024-05-212024-05-212015https://hdl.handle.net/20.500.14468/19424Our goal in this paper is to articulate a precise concept of at least a certain kind of disease-mongering, showing how pharmaceutical marketing can commercially exploit certain diseases when their best definition is given through the success of a treatment in a clinical trial. We distinguish two types of disease-mongering according to the way they exploit the definition of the trial population for marketing purposes. We argue that behind these two forms of disease-mongering there are two well-known problems in the statistical methodology of clinical trials (the reference class problem and the distinction between statistical and clinical significance). Overcoming them is far from simpleinfo:eu-repo/semantics/openAccessartículodisease-mongeringclinical trialsvaliumstatins